• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

治疗囊性纤维化肺部加重症时使用抗厌氧菌抗生素的疗效。

Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.

机构信息

Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA.

Statistics, Computing, and Analytics Research, University of Michigan, Ann Arbor, MI, USA.

出版信息

J Cyst Fibros. 2021 Nov;20(6):926-931. doi: 10.1016/j.jcf.2021.02.001. Epub 2021 Feb 19.

DOI:10.1016/j.jcf.2021.02.001
PMID:33612403
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8371065/
Abstract

BACKGROUND

Obligate and facultative anaerobic bacteria are prevalent in cystic fibrosis (CF) airways. Increases in anaerobe relative abundance have been associated with CF pulmonary exacerbations (PEx); however, the impact of antibiotic treatment of anaerobes during PEx is unknown. We hypothesized that PEx treated with antibiotics with activity against anaerobes would improve outcomes compared to antibiotics without anaerobic activity.

METHODS

This was a single-center, retrospective study of people with CF, ages 6 years and older, treated with intravenous (IV) antibiotics for PEx. IV antibiotics were classified as either broad or minimal anaerobic activity. PEx treated with broad anaerobe coverage were propensity-score matched to PEx treated with minimal anaerobic coverage. The primary outcome, % of baseline % predicted forced expiratory volume in one second (ppFEV) recovered, was compared between antibiotic categories with a linear mixed model. The secondary outcome, time to next PEx, was assessed using a Prentice Williams Petersen model.

RESULTS

514 PEx from 182 patients were included. Broad anaerobe coverage was used in 27% of PEx, and was used more often for older patients (p < 0.001) with worse baseline ppFEV (p < 0.001), and with Achromobacter (p < 0.001) or Burkholderia infections (p = 0.002). In the matched PEx, broad anaerobe coverage was not a significant predictor of % of baseline ppFEV recovered (∆ppFEV = -2.4, p = 0.09). Broad anaerobe coverage was also not a significant predictor of time to next PEx (HR 0.89, 95% CI 0.7-1.13, p = 0.35).

CONCLUSIONS

In this single center, retrospective study, antibiotics with broad activity against anaerobes were not associated with improved outcomes of CF PEx.

摘要

背景

需氧和兼性厌氧菌在囊性纤维化(CF)气道中很常见。厌氧菌相对丰度的增加与 CF 肺部恶化(PEx)有关;然而,在 PEx 期间用抗生素治疗厌氧菌的影响尚不清楚。我们假设用对厌氧菌有活性的抗生素治疗 PEx 会比用没有厌氧菌活性的抗生素治疗效果更好。

方法

这是一项针对年龄在 6 岁及以上的 CF 患者的单中心、回顾性研究,他们因 PEx 接受了静脉(IV)抗生素治疗。IV 抗生素分为广谱或最小厌氧活性。用广谱厌氧菌覆盖治疗的 PEx 与用最小厌氧菌覆盖治疗的 PEx 进行倾向评分匹配。主要结局指标,即恢复的基线预测用力呼气量(ppFEV)的百分比,用线性混合模型在抗生素类别之间进行比较。次要结局指标,即下一次 PEx 的时间,使用 Prentice Williams Petersen 模型进行评估。

结果

共纳入 182 例患者的 514 次 PEx。27%的 PEx 使用了广谱厌氧菌覆盖,且更常用于年龄较大(p<0.001)、基线 ppFEV 较差(p<0.001)、以及患有不动杆菌(p<0.001)或伯克霍尔德菌感染(p=0.002)的患者。在匹配的 PEx 中,广谱厌氧菌覆盖不是恢复的基线 ppFEV 的百分比的显著预测因素(∆ppFEV=-2.4,p=0.09)。广谱厌氧菌覆盖也不是下一次 PEx 时间的显著预测因素(HR 0.89,95%CI 0.7-1.13,p=0.35)。

结论

在这项单中心、回顾性研究中,对厌氧菌有广泛活性的抗生素与 CF PEx 的改善结局无关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2eb/8371065/435d5ff41b46/nihms-1673917-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2eb/8371065/435d5ff41b46/nihms-1673917-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2eb/8371065/435d5ff41b46/nihms-1673917-f0001.jpg

相似文献

1
Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.治疗囊性纤维化肺部加重症时使用抗厌氧菌抗生素的疗效。
J Cyst Fibros. 2021 Nov;20(6):926-931. doi: 10.1016/j.jcf.2021.02.001. Epub 2021 Feb 19.
2
The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.口服和静脉用抗菌药物对囊性纤维化肺部恶化恢复的影响。
J Cyst Fibros. 2021 Nov;20(6):932-936. doi: 10.1016/j.jcf.2021.02.012. Epub 2021 Mar 5.
3
Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations.静脉用抗假单胞菌抗生素数量与儿童囊性纤维化肺部加重的临床结局之间的关联。
Clin Infect Dis. 2021 Nov 2;73(9):1589-1596. doi: 10.1093/cid/ciab525.
4
Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.囊性纤维化儿童肺部感染加重治疗期间抗生素方案的改变。
Ann Am Thorac Soc. 2023 Sep;20(9):1293-1298. doi: 10.1513/AnnalsATS.202301-078OC.
5
Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.辅助全身皮质类固醇治疗囊性纤维化肺部加重。
Ann Am Thorac Soc. 2024 May;21(5):716-726. doi: 10.1513/AnnalsATS.202308-673OC.
6
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.标准化治疗肺部加重(STOP)研究:囊性纤维化肺部加重静脉内抗生素治疗开始时的观察。
J Cyst Fibros. 2017 Sep;16(5):592-599. doi: 10.1016/j.jcf.2017.04.005. Epub 2017 Apr 29.
7
Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment.阿奇霉素和妥布霉素联合使用对囊性纤维化肺部感染加重治疗的影响。
Ann Am Thorac Soc. 2021 Feb;18(2):266-272. doi: 10.1513/AnnalsATS.202002-176OC.
8
Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.全身性皮质类固醇在儿童囊性纤维化肺部加重期治疗中的应用
Ann Am Thorac Soc. 2023 Jan;20(1):75-82. doi: 10.1513/AnnalsATS.202203-201OC.
9
Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations.吸入性抗生素联合标准静脉治疗与儿科住院肺部恶化患者结局的相关性。
Ann Am Thorac Soc. 2020 Dec;17(12):1590-1598. doi: 10.1513/AnnalsATS.202002-179OC.
10
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.标准化治疗肺部加重(STOP)研究:患有肺部加重的囊性纤维化患者的医生治疗实践和结果。
J Cyst Fibros. 2017 Sep;16(5):600-606. doi: 10.1016/j.jcf.2017.04.003. Epub 2017 Apr 29.

引用本文的文献

1
Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis.临床微生物学实验室实用指南:更新的囊性纤维化患者呼吸道样本处理指南。
Clin Microbiol Rev. 2024 Sep 12;37(3):e0021521. doi: 10.1128/cmr.00215-21. Epub 2024 Aug 19.
2
Therapeutic beta-lactam dosages and broad-spectrum antibiotics are associated with reductions in microbial richness and diversity in persons with cystic fibrosis.治疗用β-内酰胺类药物和广谱抗生素与囊性纤维化患者微生物丰富度和多样性的减少有关。
Sci Rep. 2023 Jan 21;13(1):1217. doi: 10.1038/s41598-023-27628-x.
3

本文引用的文献

1
Maintenance tobramycin primarily affects untargeted bacteria in the CF sputum microbiome.维持妥布霉素主要影响 CF 痰液微生物组中未靶向的细菌。
Thorax. 2020 Sep;75(9):780-790. doi: 10.1136/thoraxjnl-2019-214187. Epub 2020 Jul 6.
2
Microbiome networks and change-point analysis reveal key community changes associated with cystic fibrosis pulmonary exacerbations.微生物组网络和变化点分析揭示了与囊性纤维化肺部恶化相关的关键群落变化。
NPJ Biofilms Microbiomes. 2019 Jan 21;5(1):4. doi: 10.1038/s41522-018-0077-y. eCollection 2019.
3
Good cop, bad cop: anaerobes in cystic fibrosis airways.
Multi-Omics Study of Keystone Species in a Cystic Fibrosis Microbiome.
多组学研究囊性纤维化微生物组中的关键种。
Int J Mol Sci. 2021 Nov 7;22(21):12050. doi: 10.3390/ijms222112050.
红脸白脸:囊性纤维化气道中的厌氧菌
Eur Respir J. 2018 Jul 11;52(1). doi: 10.1183/13993003.01146-2018. Print 2018 Jul.
4
Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study.从囊性纤维化气道中培养的厌氧菌与疾病的轻度相关:一项多中心研究。
Eur Respir J. 2018 Jul 11;52(1). doi: 10.1183/13993003.00242-2018. Print 2018 Jul.
5
Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis.气道细菌群落随囊性纤维化临床状态和疾病阶段的波动。
PLoS One. 2018 Mar 9;13(3):e0194060. doi: 10.1371/journal.pone.0194060. eCollection 2018.
6
Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.肺加重标准化治疗2(STOP2)的研究设计考量:一项比较囊性纤维化患者静脉抗生素治疗时长的试验
Contemp Clin Trials. 2018 Jan;64:35-40. doi: 10.1016/j.cct.2017.11.012. Epub 2017 Nov 21.
7
Airway microbiota across age and disease spectrum in cystic fibrosis.囊性纤维化患者气道微生物组的年龄与疾病谱特征。
Eur Respir J. 2017 Nov 16;50(5). doi: 10.1183/13993003.00832-2017. Print 2017 Nov.
8
The effects of inhaled aztreonam on the cystic fibrosis lung microbiome.吸入性氨曲南对囊性纤维化肺部微生物组的影响。
Microbiome. 2017 May 5;5(1):51. doi: 10.1186/s40168-017-0265-7.
9
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.标准化治疗肺部加重(STOP)研究:囊性纤维化肺部加重静脉内抗生素治疗开始时的观察。
J Cyst Fibros. 2017 Sep;16(5):592-599. doi: 10.1016/j.jcf.2017.04.005. Epub 2017 Apr 29.
10
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.标准化治疗肺部加重(STOP)研究:患有肺部加重的囊性纤维化患者的医生治疗实践和结果。
J Cyst Fibros. 2017 Sep;16(5):600-606. doi: 10.1016/j.jcf.2017.04.003. Epub 2017 Apr 29.